Symbols / VRTX
VRTX Chart
About
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 117.08B |
| Enterprise Value | 112.50B | Income | 3.95B | Sales | 12.00B |
| Book/sh | 73.49 | Cash/sh | 26.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 6400 | IPO | — |
| P/E | 30.12 | Forward P/E | 21.08 | PEG | — |
| P/S | 9.75 | P/B | 6.27 | P/C | — |
| EV/EBITDA | 23.12 | EV/Sales | 9.37 | Quick Ratio | 2.24 |
| Current Ratio | 2.90 | Debt/Eq | 10.91 | LT Debt/Eq | — |
| EPS (ttm) | 15.30 | EPS next Y | 21.87 | EPS Growth | 32.90% |
| Revenue Growth | 9.50% | Earnings | 2026-05-04 | ROA | 12.16% |
| ROE | 22.54% | ROIC | — | Gross Margin | 53.66% |
| Oper. Margin | 39.60% | Profit Margin | 32.94% | Shs Outstand | 254.03M |
| Shs Float | 253.28M | Short Float | 1.98% | Short Ratio | 2.78 |
| Short Interest | — | 52W High | 519.68 | 52W Low | 362.50 |
| Beta | 0.32 | Avg Volume | 1.42M | Volume | 1.18M |
| Target Price | $538.11 | Recom | Buy | Prev Close | $456.69 |
| Price | $460.87 | Change | 0.92% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$538.11
Mean price target
2. Current target
$460.87
Latest analyst target
3. DCF / Fair value
$182.32
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$460.87
Low
$330.00
High
$641.00
Mean
$538.11
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-17 | main | Canaccord Genuity | Hold → Hold | $441 |
| 2026-02-17 | main | Barclays | Overweight → Overweight | $607 |
| 2026-02-17 | main | HC Wainwright & Co. | Buy → Buy | $591 |
| 2026-02-13 | main | Scotiabank | Sector Perform → Sector Perform | $558 |
| 2026-02-13 | main | RBC Capital | Outperform → Outperform | $541 |
| 2026-02-13 | main | Stifel | Hold → Hold | $466 |
| 2026-02-13 | up | Oppenheimer | Perform → Outperform | $540 |
| 2026-02-13 | main | HC Wainwright & Co. | Buy → Buy | $518 |
| 2026-01-28 | up | Barclays | Equal-Weight → Overweight | $606 |
| 2026-01-26 | main | UBS | Buy → Buy | $545 |
| 2026-01-23 | main | Evercore ISI Group | Outperform → Outperform | $530 |
| 2026-01-22 | up | RBC Capital | Sector Perform → Outperform | $546 |
| 2026-01-12 | up | Bernstein | Market Perform → Outperform | — |
| 2026-01-06 | up | Wolfe Research | Peer Perform → Outperform | $548 |
| 2025-12-29 | main | Leerink Partners | Outperform → Outperform | $525 |
| 2025-12-10 | main | Wells Fargo | Overweight → Overweight | $515 |
| 2025-12-05 | main | Morgan Stanley | Overweight → Overweight | $564 |
| 2025-12-03 | up | Morgan Stanley | Equal-Weight → Overweight | $516 |
| 2025-11-07 | main | UBS | Buy → Buy | $546 |
| 2025-11-04 | main | RBC Capital | Sector Perform → Sector Perform | $415 |
- Experimental kidney drug slashes protein in urine in major Vertex trial - Stock Titan Mon, 09 Mar 2026 20
- Wolfe Research reiterates Vertex stock rating on IgAN trial data - Investing.com Mon, 09 Mar 2026 22
- Vertex Stock Pre-Market (+4.7%): Positive Phase 3 Kidney Drug Data - Trefis ue, 10 Mar 2026 06
- A Look At Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Choppiness - simplywall.st ue, 10 Mar 2026 04
- Vertex Pharmaceuticals (VRTX) Stock Rises 5% on Kidney Drug Trial Win - CoinCentral ue, 10 Mar 2026 10
- Vertex jumps after positive Phase 3 interim data for povetacicept in IgA nephropathy - Quiver Quantitative Mon, 09 Mar 2026 21
- Vertex Pharmaceuticals Stock Jumps After The Close: Here's Why - Benzinga Mon, 09 Mar 2026 20
- US Stock Movement | Vertex Pharmaceuticals (VRTX.US) surges after hours as late-stage trial of kidney drug povetacicept meets expected targets - Bitget ue, 10 Mar 2026 00
- Vertex Pharmaceuticals (VRTX) Surges 7% Following Promising Tria - GuruFocus Mon, 09 Mar 2026 23
- Nasdaq, S&P 500 Futures Turn Green On Iran War De-Escalation Signals: Why NVDA, ORCL, JOBY, VRTX, ZVRA Are On Traders' Radar Today - Stocktwits ue, 10 Mar 2026 08
- Vertex to Participate in Upcoming March Investor Conferences - Business Wire hu, 05 Mar 2026 21
- Vertex Pharmaceuticals Posted $12 Billion in Revenue Last Year: Analysts Point to a $815 Stock Price - TIKR.com Wed, 04 Mar 2026 14
- VRTX Soars In Extended Hours After Experimental Drug Shows Positive Changes In Autoimmune Kidney Disease - Stocktwits Mon, 09 Mar 2026 16
- Non-opioid pain pill and gene therapy help fuel Vertex’s $12B year - Stock Titan hu, 12 Feb 2026 08
- Vertex Pharmaceuticals (VRTX) Gains on Positive Trial Results - GuruFocus ue, 10 Mar 2026 10
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2437 | 1158306 | — | Sale at price 475.30 per share. | MCKECHNIE DUNCAN | Officer | — | 2026-03-04 00:00:00 | D |
| 1 | 892 | 442396 | — | Sale at price 495.96 per share. | LIU JOY | Officer | — | 2026-03-02 00:00:00 | D |
| 2 | 2329 | 1118642 | — | Sale at price 480.31 per share. | BOZIC CARMEN | Officer | — | 2026-02-27 00:00:00 | D |
| 3 | 40000 | 19738855 | — | Sale at price 479.75 - 496.95 per share. | KEWALRAMANI RESHMA | Chief Executive Officer | — | 2026-02-27 00:00:00 | D |
| 4 | 357 | 172560 | — | Sale at price 483.36 per share. | AMBROSE KRISTEN | Officer | — | 2026-02-26 00:00:00 | D |
| 5 | 668 | 324882 | — | Sale at price 486.35 per share. | ATKINSON EDWARD MORROW III | Chief Technology Officer | — | 2026-02-25 00:00:00 | D |
| 6 | 4910 | 2394365 | — | Sale at price 486.35 - 489.00 per share. | MCKECHNIE DUNCAN | Officer | — | 2026-02-25 00:00:00 | D |
| 7 | 620 | 301537 | — | Sale at price 486.35 per share. | BUNNAGE MARK E. | Officer | — | 2026-02-25 00:00:00 | D |
| 8 | 223 | 108456 | — | Sale at price 486.35 per share. | AMBROSE KRISTEN | Officer | — | 2026-02-25 00:00:00 | D |
| 9 | 260 | 126451 | — | Sale at price 486.35 per share. | TATSIS OURANIA | Officer | — | 2026-02-25 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -56.63M | 105.00K | 8.98M | 12.36M |
| TaxRateForCalcs | 0.15 | 0.21 | 0.17 | 0.21 |
| NormalizedEBITDA | 5.25B | 485.80M | 4.55B | 4.38B |
| TotalUnusualItems | -381.10M | 500.00K | 51.60M | 57.50M |
| TotalUnusualItemsExcludingGoodwill | -381.10M | 500.00K | 51.60M | 57.50M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 3.95B | -535.60M | 3.62B | 3.32B |
| ReconciledDepreciation | 209.80M | 207.20M | 181.30M | 148.30M |
| ReconciledCostOfRevenue | 1.65B | 1.53B | 1.26B | 1.08B |
| EBITDA | 4.87B | 486.30M | 4.61B | 4.44B |
| EBIT | 4.66B | 279.10M | 4.42B | 4.29B |
| NetInterestIncome | 477.60M | 567.50M | 570.60M | 89.80M |
| InterestExpense | 13.30M | 30.60M | 44.10M | 54.80M |
| InterestIncome | 490.90M | 598.10M | 614.70M | 144.60M |
| NormalizedIncome | 4.28B | -536.00M | 3.58B | 3.28B |
| NetIncomeFromContinuingAndDiscontinuedOperation | 3.95B | -535.60M | 3.62B | 3.32B |
| TotalExpenses | 7.45B | 11.25B | 6.09B | 4.68B |
| TotalOperatingIncomeAsReported | 4.17B | -232.90M | 3.83B | 4.31B |
| DilutedAverageShares | 258.00M | 257.90M | 260.50M | 259.10M |
| BasicAverageShares | 255.70M | 257.90M | 257.70M | 256.10M |
| DilutedEPS | 15.32 | -2.08 | 13.89 | 12.82 |
| BasicEPS | 15.46 | -2.08 | 14.05 | 12.97 |
| DilutedNIAvailtoComStockholders | 3.95B | -535.60M | 3.62B | 3.32B |
| NetIncomeCommonStockholders | 3.95B | -535.60M | 3.62B | 3.32B |
| NetIncome | 3.95B | -535.60M | 3.62B | 3.32B |
| NetIncomeIncludingNoncontrollingInterests | 3.95B | -535.60M | 3.62B | 3.32B |
| NetIncomeContinuousOperations | 3.95B | -535.60M | 3.62B | 3.32B |
| TaxProvision | 690.00M | 784.10M | 760.20M | 910.40M |
| PretaxIncome | 4.64B | 248.50M | 4.38B | 4.23B |
| OtherIncomeExpense | -388.80M | -85.60M | 28.80M | -107.30M |
| OtherNonOperatingIncomeExpenses | -7.70M | -86.10M | -22.80M | -164.80M |
| SpecialIncomeCharges | -381.10M | 500.00K | 51.60M | 57.50M |
| OtherSpecialCharges | 4.63B | 527.10M | 115.50M | 1.11B |
| ImpairmentOfCapitalAssets | 379.00M | 0.00 | 0.00 | |
| RestructuringAndMergernAcquisition | 2.10M | -500.00K | -51.60M | -57.50M |
| NetNonOperatingInterestIncomeExpense | 477.60M | 567.50M | 570.60M | 89.80M |
| InterestExpenseNonOperating | 13.30M | 30.60M | 44.10M | 54.80M |
| InterestIncomeNonOperating | 490.90M | 598.10M | 614.70M | 144.60M |
| OperatingIncome | 4.55B | -233.40M | 3.78B | 4.25B |
| OperatingExpense | 5.80B | 9.72B | 4.83B | 3.60B |
| ResearchAndDevelopment | 4.04B | 8.26B | 3.69B | 2.66B |
| SellingGeneralAndAdministration | 1.75B | 1.46B | 1.14B | 944.70M |
| GrossProfit | 10.35B | 9.49B | 8.61B | 7.85B |
| CostOfRevenue | 1.65B | 1.53B | 1.26B | 1.08B |
| TotalRevenue | 12.00B | 11.02B | 9.87B | 8.93B |
| OperatingRevenue | 11.97B | 11.02B | 9.87B | 8.93B |
| Line Item | 2023-12-31 | 2022-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | 0.00 | ||
| OrdinarySharesNumber | 253.99M | 256.94M | 257.70M | 257.01M |
| ShareIssued | 253.99M | 256.94M | 257.70M | 257.01M |
| TotalDebt | 2.03B | 1.74B | 808.40M | 899.70M |
| TangibleBookValue | 17.15B | 14.50B | 15.65B | 12.22B |
| InvestedCapital | 18.67B | 16.41B | 17.58B | 13.91B |
| WorkingCapital | 7.34B | 6.03B | 10.60B | 10.49B |
| NetTangibleAssets | 17.15B | 14.50B | 15.65B | 12.22B |
| CapitalLeaseObligations | 2.03B | 1.74B | 808.40M | 899.70M |
| CommonStockEquity | 18.67B | 16.41B | 17.58B | 13.91B |
| TotalCapitalization | 18.67B | 16.41B | 17.58B | 13.91B |
| TotalEquityGrossMinorityInterest | 18.67B | 16.41B | 17.58B | 13.91B |
| StockholdersEquity | 18.67B | 16.41B | 17.58B | 13.91B |
| GainsLossesNotAffectingRetainedEarnings | -15.90M | 127.80M | -14.30M | 800.00K |
| OtherEquityAdjustments | -15.90M | 127.80M | -14.30M | 800.00K |
| RetainedEarnings | 13.56B | 9.61B | 10.14B | 6.52B |
| AdditionalPaidInCapital | 5.12B | 6.67B | 7.45B | 7.39B |
| CapitalStock | 2.50M | 2.60M | 2.60M | 2.60M |
| CommonStock | 2.50M | 2.60M | 2.60M | 2.60M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 6.98B | 6.12B | 5.15B | 4.24B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 3.12B | 2.56B | 1.60B | 1.50B |
| OtherNonCurrentLiabilities | 267.40M | 203.20M | 196.30M | 233.00M |
| TradeandOtherPayablesNonCurrent | 895.40M | 698.60M | 681.40M | 452.80M |
| LongTermDebtAndCapitalLeaseObligation | 1.95B | 1.66B | 724.70M | 810.30M |
| LongTermCapitalLeaseObligation | 1.95B | 1.66B | 724.70M | 810.30M |
| CurrentLiabilities | 3.86B | 3.56B | 3.55B | 2.74B |
| OtherCurrentLiabilities | 127.70M | 36.60M | 50.70M | 62.50M |
| CurrentDeferredLiabilities | 171.80M | 206.80M | 170.30M | 159.60M |
| CurrentDeferredRevenue | 171.80M | 206.80M | 170.30M | 159.60M |
| CurrentDebtAndCapitalLeaseObligation | 77.30M | 87.10M | 83.70M | 89.40M |
| CurrentCapitalLeaseObligation | 77.30M | 87.10M | 83.70M | 89.40M |
| PayablesAndAccruedExpenses | 3.48B | 3.23B | 3.24B | 2.43B |
| CurrentAccruedExpenses | 2.59B | 2.36B | 2.32B | 1.79B |
| Payables | 893.00M | 877.60M | 924.50M | 642.20M |
| OtherPayable | 328.20M | 303.50M | 460.10M | 215.00M |
| TotalTaxPayable | 103.10M | 161.10M | 99.50M | 123.30M |
| AccountsPayable | 461.70M | 413.00M | 364.90M | 303.90M |
| TotalAssets | 25.64B | 22.53B | 22.73B | 18.15B |
| TotalNonCurrentAssets | 14.44B | 12.94B | 8.59B | 4.92B |
| OtherNonCurrentAssets | 1.24B | 999.30M | 895.30M | 409.60M |
| NonCurrentDeferredAssets | 2.90B | 2.33B | 1.81B | 1.25B |
| NonCurrentDeferredTaxesAssets | 2.90B | 2.33B | 1.81B | 1.25B |
| InvestmentsAndAdvances | 5.71B | 5.11B | 2.50B | 112.20M |
| InvestmentinFinancialAssets | 5.71B | 5.11B | 2.50B | 112.20M |
| AvailableForSaleSecurities | 5.71B | 5.11B | 2.50B | 112.20M |
| GoodwillAndOtherIntangibleAssets | 1.51B | 1.91B | 1.93B | 1.69B |
| OtherIntangibleAssets | 424.20M | 825.90M | 839.90M | 603.60M |
| Goodwill | 1.09B | 1.09B | 1.09B | 1.09B |
| NetPPE | 3.08B | 2.58B | 1.45B | 1.46B |
| AccumulatedDepreciation | -1.20B | -1.06B | -1.19B | -1.03B |
| GrossPPE | 4.29B | 3.65B | 2.64B | 2.48B |
| Leases | 1.01B | 737.60M | 474.60M | 410.90M |
| OtherProperties | 1.56B | 1.36B | 293.60M | 347.40M |
| MachineryFurnitureEquipment | 1.20B | 1.06B | 911.90M | 788.60M |
| BuildingsAndImprovements | 483.80M | 461.20M | 928.60M | 903.10M |
| LandAndImprovements | 33.10M | 33.10M | 33.10M | 33.10M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 11.20B | 9.60B | 14.14B | 13.23B |
| OtherCurrentAssets | 110.90M | 76.40M | 84.30M | 74.40M |
| HedgingAssetsCurrent | 6.20M | 130.10M | 1.80M | 47.50M |
| PrepaidAssets | 736.20M | 459.20M | 537.60M | 431.60M |
| Inventory | 1.69B | 1.21B | 738.80M | 460.60M |
| FinishedGoods | 230.10M | 184.60M | 135.00M | 161.80M |
| WorkInProcess | 1.20B | 768.80M | 525.10M | 260.70M |
| RawMaterials | 259.80M | 252.00M | 78.70M | 38.10M |
| Receivables | 2.05B | 1.61B | 1.56B | 1.44B |
| AccountsReceivable | 2.05B | 1.61B | 1.56B | 1.44B |
| CashCashEquivalentsAndShortTermInvestments | 6.61B | 6.12B | 11.22B | 10.78B |
| OtherShortTermInvestments | 1.52B | 1.55B | 849.20M | 274.50M |
| CashAndCashEquivalents | 5.08B | 4.57B | 10.37B | 10.50B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 3.19B | -978.00M | 3.28B | 3.93B |
| RepurchaseOfCapitalStock | -2.39B | -1.58B | -653.70M | -172.00M |
| RepaymentOfDebt | -5.40M | -33.60M | -44.90M | -85.50M |
| IssuanceOfDebt | 1.80M | 0.00 | 28.30M | |
| CapitalExpenditure | -437.60M | -485.40M | -258.40M | -204.70M |
| InterestPaidSupplementalData | 12.40M | 30.50M | 43.10M | 52.30M |
| IncomeTaxPaidSupplementalData | 1.57B | 1.08B | 1.68B | 1.06B |
| EndCashPosition | 5.09B | 4.57B | 10.37B | 10.51B |
| BeginningCashPosition | 4.57B | 10.37B | 10.51B | 6.80B |
| EffectOfExchangeRateChanges | 90.90M | -42.60M | 26.90M | -29.20M |
| ChangesInCash | 424.70M | -5.76B | -166.60M | 3.74B |
| FinancingCashFlow | -2.26B | -1.49B | -562.20M | -67.70M |
| CashFlowFromContinuingFinancingActivities | -2.26B | -1.49B | -562.20M | -67.70M |
| NetOtherFinancingCharges | 3.70M | 6.20M | 1.80M | 3.50M |
| ProceedsFromStockOptionExercised | 127.70M | 114.60M | 134.60M | 186.30M |
| NetCommonStockIssuance | -2.39B | -1.58B | -653.70M | -172.00M |
| CommonStockPayments | -2.39B | -1.58B | -653.70M | -172.00M |
| NetIssuancePaymentsOfDebt | -5.40M | -33.60M | -44.90M | -85.50M |
| NetLongTermDebtIssuance | -5.40M | -33.60M | -44.90M | -85.50M |
| LongTermDebtPayments | -5.40M | -33.60M | -44.90M | -85.50M |
| LongTermDebtIssuance | 1.80M | 0.00 | 28.30M | |
| InvestingCashFlow | -945.40M | -3.77B | -3.14B | -321.10M |
| CashFlowFromContinuingInvestingActivities | -945.40M | -3.77B | -3.14B | -321.10M |
| NetOtherInvestingChanges | -24.70M | -54.00M | -31.00M | -47.80M |
| NetInvestmentPurchaseAndSale | -483.10M | -3.23B | -2.85B | 227.30M |
| SaleOfInvestment | 5.91B | 4.47B | 934.20M | 920.00M |
| PurchaseOfInvestment | -6.40B | -7.70B | -3.79B | -692.70M |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | -295.90M | 0.00 |
| PurchaseOfBusiness | 0.00 | 0.00 | -295.90M | 0.00 |
| NetIntangiblesPurchaseAndSale | 0.00 | -187.70M | -58.00M | 0.00 |
| PurchaseOfIntangibles | 0.00 | -187.70M | -58.00M | 0.00 |
| NetPPEPurchaseAndSale | -437.60M | -297.70M | -200.40M | -204.70M |
| PurchaseOfPPE | -437.60M | -297.70M | -200.40M | -204.70M |
| OperatingCashFlow | 3.63B | -492.60M | 3.54B | 4.13B |
| CashFlowFromContinuingOperatingActivities | 3.63B | -492.60M | 3.54B | 4.13B |
| ChangeInWorkingCapital | -1.20B | -514.80M | -265.70M | 340.80M |
| ChangeInOtherCurrentLiabilities | 148.50M | 39.70M | 208.90M | 498.90M |
| ChangeInPayablesAndAccruedExpense | -80.10M | 262.40M | 478.10M | 663.30M |
| ChangeInAccruedExpense | -116.90M | 212.90M | 429.40M | 542.50M |
| ChangeInPayable | 36.80M | 49.50M | 48.70M | 120.80M |
| ChangeInAccountPayable | 36.80M | 49.50M | 48.70M | 120.80M |
| ChangeInPrepaidAssets | -396.00M | -200.30M | -545.70M | -326.40M |
| ChangeInInventory | -524.20M | -517.30M | -322.90M | -136.40M |
| ChangeInReceivables | -347.30M | -99.30M | -84.10M | -358.60M |
| ChangesInAccountReceivables | -347.30M | -99.30M | -84.10M | -358.60M |
| OtherNonCashItems | 113.40M | 900.00K | -42.60M | -45.70M |
| StockBasedCompensation | 685.90M | 698.50M | 581.20M | 491.30M |
| AssetImpairmentCharge | 379.00M | 0.00 | 0.00 | |
| DeferredTax | -510.80M | -348.80M | -536.50M | -275.90M |
| DeferredIncomeTax | -510.80M | -348.80M | -536.50M | -275.90M |
| DepreciationAmortizationDepletion | 209.80M | 207.20M | 181.30M | 148.30M |
| DepreciationAndAmortization | 209.80M | 207.20M | 181.30M | 148.30M |
| Depreciation | 148.30M | 125.60M | ||
| OperatingGainsLosses | 57.70M | 600.00K | 149.10M | -17.10M |
| GainLossOnInvestmentSecurities | 57.70M | 600.00K | 149.10M | -17.10M |
| NetIncomeFromContinuingOperations | 3.95B | -535.60M | 3.62B | 3.32B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for VRTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|